A Phase II Study of SGN-15 (cBR96 – Doxorubicin Immunoconjugate) Combined With Gemzar Versus Single-Agent Gemzar in Patients With Advanced Ovarian Cancer

Trial Profile

A Phase II Study of SGN-15 (cBR96 – Doxorubicin Immunoconjugate) Combined With Gemzar Versus Single-Agent Gemzar in Patients With Advanced Ovarian Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2011

At a glance

  • Drugs Gemcitabine; SGN-15
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2011 Seattle Genetics as company and lead trial centre added as reported by ClinicalTrials.gov.
    • 16 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top